Neogen (NEOG) reported $870M in revenue for fiscal 2025, −2.7% year on year. That ranks #1861 by revenue among 2853 SEC filers and #172 in Healthcare. It posted a net loss of −$7.9M for the same year. Revenue has grown 10.5% a year on average since 2015 ($321M then). The fiscal 2025 balance sheet shows $3.4B in total assets, $145M in cash and $793M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $870M | −2.7% | FY20252026-05-31 |
| Gross profitGrossProfit | $409M | −3.1% | FY20252026-05-31 |
| Operating incomeOperatingIncomeLoss | −$21.6M | +$1.0B | FY20252026-05-31 |
| Net incomeNetIncomeLoss | −$7.9M | +$1.1B | FY20252026-05-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $83.2M | +43.0% | FY20252026-05-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $51.3M | −51.0% | FY20252026-05-31 |
| Total assetsAssets | $3.4B | −17.1% | FY20252025-11-30 |
| Shareholders' equityStockholdersEquity | $2.1B | −21.2% | FY20252025-11-30 |
| CashCashAndCashEquivalentsAtCarryingValue | $145M | +3.6% | FY20252025-11-30 |
| Long-term debtLongTermDebtNoncurrent | $793M | −10.9% | FY20252025-11-30 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-02-28 | $211M | −$17.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Neogen Corp
- Ticker
- NEOG
- Exchange
- Nasdaq
- SIC classification
- In Vitro & In Vivo Diagnostic Substances (2835)
- Fiscal year end
- 05-31
- CIK
- 0000711377
Filings
- 10-KJul 30, 2026Open filing →
- 10-QApr 9, 2026Open filing →
- 10-QJan 8, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ani PharmaceuticalsANIP | $883M | $78.0M |
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
| Warby ParkerWRBY | $872M | $1.6M |
| NeogenNEOG | $870M | −$7.9M |
| Harmony BiosciencesHRMY | $868M | $159M |
| Innovage HoldingINNV | $854M | −$30.3M |
| Arrowhead PharmaceuticalsARWR | $829M | −$1.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neogen — Key figures |url=https://companiesranked.com/en/company/neogen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neogen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/neogenBibTeX
@misc{companiesranked-en-company-neogen-2026,
author = {{CompaniesRanked}},
title = {{Neogen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neogen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-326092 · July 30, 2026
{{cite web |title=Neogen — Key figures — 10-K (0001193125-26-326092) |url=https://www.sec.gov/Archives/edgar/data/711377/000119312526326092/neog-20260531.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-30}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.